Senior UK ophthalmologists up in arms over ISTC scheme

Article

Senior doctors have accused the independent sector treatment centre (ISTC) scheme for NHS cataract services of being an expensive over-reaction to the need to increase the rate of cataract surgery in the UK.

In a letter to the British Medical Journal (BMJ), senior doctors have accused the independent sector treatment centre (ISTC) scheme for NHS cataract services of being an expensive over-reaction to the need to increase the rate of cataract surgery in the UK.

The letter, co-signed by Simon Kelly (Consultant Ophthalmic Surgeon), the President and Vice President of the Royal College of Ophthalmologists and the Chair of the British Medical Association's Ophthalmic Group Committee, points out that many ophthalmology departments have already improved cataract surgery pathways before the ISTC programme was even proposed.

It goes on to claim that, had the Department of Health listened to the advice of clinicians, colleges and the British Medical Association (BMA), improved access could have been provided with much less expenditure, without causing adverse effects on surgical training and without destabilizing NHS eye departments.

However, despite the lack of clinical outcome data and evidence of cost effectiveness of phase 1 of the ISTC programme, further investment in cataract surgical facilities has continued into a second phase.

According to the complainants, the best option for long-term stability of the UK cataract services is for the public to support local NHS units.

An ISTC is a unit run by an independent sector provider and commissioned by the UK's Primary Care Trust (PCT) to offer ophthalmic treatment and diagnostic services. The UK Government's purpose for these centres was to reduce waiting times and to drive improvements in quality and efficiency.

The authors strongly suggest that constructive partnerships between clinicians, managers and commissioners are a better way to achieve sustained improvements, rather than centrally imposed initiatives, such as the cataract ISTC scheme.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.